세계의 루프 매개 등온증폭(LAMP) 시장 예측(-2030년) : 제품 유형, 유형, 기술, 응용 분야, 최종 사용자 및 지역별 분석

According to Stratistics MRC, the Global Loop-mediated Isothermal Amplification Market is accounted for $103.5 million in 2023 and is expected to reach $165.1 million by 2030 growing at a CAGR of 6.9% during the forecast period. Loop-mediated isothermal amplification (LAMP) is a nucleic acid amplification technique used to rapidly replicate DNA under constant temperature conditions. It employs four to six primers targeting multiple regions of the DNA, including loop structures, which initiate strand displacement and amplification. LAMP reactions typically occur between 60-65°C, eliminating the need for thermal cycling equipment. By producing large amounts of DNA within 30-60 minutes, LAMP enables rapid detection of target sequences, such as pathogens or genetic variations. Its simplicity, speed, and high specificity make it valuable in various fields, including clinical diagnostics, environmental monitoring, and food safety testing.

Market Dynamics:

Driver:

Rising demand for rapid and accurate diagnostics

The increasing need for quick and precise diagnostics has propelled the growth of the LAMP market. Healthcare providers are adopting loop-mediated isothermal amplification technology to meet the demand for rapid testing, especially in scenarios where timely diagnosis is critical, such as infectious disease outbreaks or emergency situations. Companies are investing in research and development to improve the sensitivity, specificity, and multiplexing capabilities of loop-mediated isothermal amplification assays. This has led to the development of advanced loop-mediated isothermal amplification-based diagnostic platforms and reagents boosting the growth of the market.

Restraint:

Limited multiplexing capability

Limited multiplexing capability means that each target must be detected in a separate reaction, increasing the time, cost, and resources required for diagnostics. This reduced efficiency and cost-effectiveness can deter healthcare providers from adopting loop-mediated isothermal amplification technology, especially in settings where high throughput and resource efficiency are crucial. Thus the limited multiplexing capability of loop-mediated isothermal amplification technology can put it at a competitive disadvantage in the market, as healthcare providers may opt for alternative technologies that better meet their multiplexing needs hamper the market growth.

Opportunity:

Increasing prevalence of chronic diseases

Chronic diseases often require regular monitoring and early detection for effective management and treatment. The need for rapid and accurate diagnostic solutions to detect these diseases at an early stage has increased. LAMP technology, with its rapid turnaround time and high sensitivity, is well-suited for diagnosing chronic conditions, enabling timely intervention and improved patient outcomes. Furthermore governments and healthcare organizations worldwide are implementing screening programs to detect chronic diseases early, thereby reducing disease burden and healthcare costs.

Threat:

Limited infrastructure in resource-limited settings

Resource-limited settings often lack adequate healthcare infrastructure, including laboratory facilities, trained personnel, and reliable electricity supply. The requirement for specialized equipment and trained personnel to conduct loop-mediated isothermal amplification assays may pose accessibility challenges in such settings, limiting the adoption of this technology. Additionally, the need for uninterrupted power supply and climate-controlled storage conditions for reagents further adds to the cost burden, making LAMP technology less feasible in these environments.

Covid-19 Impact

The COVID-19 pandemic has accelerated the adoption of Loop-mediated Isothermal Amplification (LAMP) technology for rapid and decentralized testing. LAMP's simplicity, speed, and accuracy have made it a valuable tool for COVID-19 diagnostics, especially in resource-limited settings and point-of-care environments. The demand for LAMP-based assays and platforms has surged as healthcare systems seek efficient testing solutions to curb the spread of the virus. However, supply chain disruptions, regulatory challenges, and competition from other diagnostic technologies have also influenced the LAMP market dynamics during the pandemic. Overall, COVID-19 has both propelled and challenged the growth of the LAMP market.

The DNA (deoxyribonucleic acid) segment is expected to be the largest during the forecast period

The DNA (deoxyribonucleic acid) segment is estimated to have a lucrative growth, as it is designed to amplify DNA sequences. It is widely used in molecular biology research, clinical diagnostics, and various other fields where rapid and sensitive detection of DNA is required. Moreover in clinical diagnostics, the presence or absence of specific DNA sequences is often indicative of disease states, genetic mutations, or pathogen infections. Loop-mediated isothermal amplification assays are designed to detect these DNA targets with high sensitivity and specificity. Therefore, the availability of loop-mediated isothermal amplification assays that can accurately amplify and detect target DNA sequences influences the adoption and growth of the LAMP market in diagnostic applications.

The reverse transcription LAMP segment is expected to have the highest CAGR during the forecast period

The reverse transcription LAMP segment is anticipated to witness the highest CAGR growth during the forecast period, as it allows for the amplification of RNA targets, in addition to DNA, which significantly broadens the application spectrum of LAMP technology. This expansion enables the detection of RNA viruses, RNA-based biomarkers, and RNA transcripts, opening up new opportunities in infectious disease diagnosis, gene expression analysis, and RNA research. Furthermore this capability is useful in gene expression profiling studies, biomarker discovery, and monitoring cellular responses to stimuli or treatments thus all the above factors drive the market growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the prevalence of infectious diseases in the Asia Pacific region, including tuberculosis, dengue, malaria, and emerging infectious diseases like COVID-19, is driving the demand for rapid diagnostic solutions. Its ability to provide quick and accurate results is particularly valuable in controlling disease outbreaks and managing public health challenges. Additionally the presence of a robust biotechnology and life sciences industry in countries like Japan, South Korea, China, and India fosters research and development activities in loop-mediated isothermal amplification technology propel the growth of the market.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, despite high healthcare standards; North America still faces challenges related to infectious diseases such as influenza, Lyme disease, and sexually transmitted infections. LAMP technology's rapid and accurate diagnostic capabilities make it attractive for healthcare providers in the region. The demand for decentralized testing solutions is increasing in North America, especially in remote or underserved areas and during public health emergencies encourage the growth of the market.

Key players in the market

Some of the key players in the Loop-mediated Isothermal Amplification Market include Bio-Rad Laboratories, Inc., CapitalBio, Deaou Biotechnology, Eiken Chemical , Excellgen Inc, GENESIS Dhelix, HiberGene Diagnostics, Jena Bioscience GmbH, Mast Group Ltd., Merck KGaA, Meridian Bioscience, Inc., New England Biolabs, NIPPON GENE CO., LTD, OptiGene, QIAGEN N.V, Singuway and Thermo Fisher Scientific

Key Developments:

In March 2024, Thermo Fisher Scientific Launches CorEvitas Clinical Registry in Generalized Pustular Psoriasis. This registry, which is open to enrollment, is CorEvitas' 10th syndicated disease registry and addresses an unmet need for real-world evidence (RWE) related to the clinical and patient-reported outcomes of patients with GPP.

In January 2024, Nippon Gene Co., Ltd. announced the National Agriculture and Food Research Organization (NARO) have developed two molecular-based diagnostic kits for Johne's disease.

In July 2023, Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement. The settlement provides for a cross-licensing agreement between Bio-Rad and QIAGEN granting each company mutual rights to their respective digital PCR technologies.

Product Types Covered:

• Instruments
• Kits & Reagents
• Other Product Types

Types Covered:

• DNA (Deoxyribonucleic Acid)
• RNA (Ribonucleic Acid)

Technologies Covered:

• Conventional LAMP
• Reverse Transcription LAMP
• Digital LAMP
• Isothermal Multiple Self-Made Primer Amplification (IMSPA)
• Other Technologies

Applications Covered:

• Infectious Disease Diagnosis
• Veterinary Diagnostics
• Molecular Diagnostics
• Plant Disease Diagnostics
• Biodefense and Biosecurity
• Other Applications

End Users Covered:

• Research & Academic Institutes
• Hospitals & Clinics
• Veterinary Clinics
• Food & Beverage Industry
• Point-of-Care and Near-Patient Testing Sites
• Biotechnology and Pharmaceutical Companies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 Application Analysis
• 3.9 End User Analysis
• 3.10 Emerging Markets
• 3.11 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Loop-mediated Isothermal Amplification Market, By Product Type

• 5.1 Introduction
• 5.2 Instruments
  • 5.2.1 Turbidimeters
  • 5.2.2 Incubation Systems
  • 5.2.3 Agarose Gel Electrophoresis
  • 5.2.4 Fluorescence Measuring Systems
• 5.3 Kits & Reagents
  • 5.3.1 Primers
  • 5.3.2 DNA Polymerase Enzymes
  • 5.3.3 Buffers
  • 5.3.4 Detection Reagents
• 5.4 Other Product Types

6 Global Loop-mediated Isothermal Amplification Market, By Type

• 6.1 Introduction
• 6.2 DNA (Deoxyribonucleic Acid)
• 6.3 RNA (Ribonucleic Acid)

7 Global Loop-mediated Isothermal Amplification Market, By Technology

• 7.1 Introduction
• 7.2 Conventional LAMP
• 7.3 Reverse Transcription LAMP
• 7.4 Digital LAMP
• 7.5 Isothermal Multiple Self-Made Primer Amplification (IMSPA)
• 7.6 Other Technologies

8 Global Loop-mediated Isothermal Amplification Market, By Application

• 8.1 Introduction
• 8.2 Infectious Disease Diagnosis
• 8.3 Veterinary Diagnostics
• 8.4 Molecular Diagnostics
• 8.5 Plant Disease Diagnostics
• 8.6 Biodefense and Biosecurity
• 8.7 Other Applications

9 Global Loop-mediated Isothermal Amplification Market, By End User

• 9.1 Introduction
• 9.2 Research & Academic Institutes
• 9.3 Hospitals & Clinics
• 9.4 Veterinary Clinics
• 9.5 Food & Beverage Industry
• 9.6 Point-of-Care and Near-Patient Testing Sites
• 9.7 Biotechnology and Pharmaceutical Companies
• 9.8 Other End Users

10 Global Loop-mediated Isothermal Amplification Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Bio-Rad Laboratories, Inc.
• 12.2 CapitalBio
• 12.3 Deaou Biotechnology
• 12.4 Eiken Chemical
• 12.5 Excellgen, Inc.
• 12.6 GENESIS Dhelix
• 12.7 HiberGene Diagnostics
• 12.8 Jena Bioscience GmbH
• 12.9 Mast Group Ltd.
• 12.10 Merck KGaA
• 12.11 Meridian Bioscience, Inc.
• 12.12 New England Biolabs
• 12.13 NIPPON GENE CO., LTD
• 12.14 OptiGene
• 12.15 QIAGEN N.V
• 12.16 Singuway
• 12.17 Thermo Fisher Scientific